Skip to main content
Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc. — Investor Relations & Filings

Ticker · NRIX ISIN · US67080M1036 US Professional, scientific and technical activities
Open in API
Filings indexed 485 across all filing types
Latest filing 2026-05-15 Declaration of Voting R…
Country US United States of America
Listing US NRIX

About Nurix Therapeutics, Inc.

https://www.nurixtx.com/

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of medicines based on targeted protein degradation. The company's proprietary DEL-AI drug discovery engine is used to create therapies that harness the body's natural cellular machinery to eliminate disease-causing proteins. Its pipeline features multiple modalities, including small molecule degraders and Degrader Antibody Conjugates (DACs), which combine the specificity of an antibody with the catalytic potency of a degrader. These investigational therapies are being advanced for the treatment of various cancers and autoimmune diseases.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K under Item 5.07, ‘Submission of Matters to a Vote of Security Holders,’ detailing the final voting results for proposals at the company's 2026 Annual Meeting (election of directors, ratification of auditors, advisory vote on executive compensation). This precisely matches the Definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-15 English
10-Q - Nurix Therapeutics, Inc. (0001549595) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-08 English
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial results press release for the first quarter of fiscal year 2026 by Nurix Therapeutics. It includes comprehensive financial data such as revenue, operating expenses, net loss, and balance sheet items for the quarter ended February 28, 2026. The text also provides a corporate update on clinical trials and strategic collaborations. The presence of detailed financial statements and analysis for a quarterly period indicates this is an Interim / Quarterly Report. The document length (15,000 characters) and content confirm it is not a brief earnings release or a simple announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2026-04-08 English
SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
Major Shareholding Notification
2026-03-27 English
ARS - Nurix Therapeutics, Inc. (0001549595) (Filer)
Annual Report
2026-03-27 English
DEFA14A - Nurix Therapeutics, Inc. (0001549595) (Filer)
Remuneration Information Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. The text explicitly states it is a 'Definitive Additional Materials' related to a proxy statement. Proxy statements and related materials are classified under 'Remuneration Information' (DEF 14A) when they detail compensation and governance matters for executives and directors. The document length is short (1316 characters), and it is not a full annual report or other financial report. Therefore, the correct classification is DEF 14A.
2026-03-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.